영국의 소트로비맙 승인: 오미크론에 효과적인 단일클론항체, 미래 변이체에도 작용할 수 있음

Sotrovimab, a monoclonal antibody already approved for mild to moderate COVID-19 in several countries gets approval by MHRA in the UK. This antibody was intelligently designed with a mutating virus in mind. A highly conserved region of the spike protein was targeted that is less likely to mutate, with a hope to address both the previous and current 변종 of SARS-CoV-2 virus (Omicron) and the future 변종, that would be inevitable.

Xeduvy (sotrovimab), a 단일 클론 항체 made in collaboration between GSK and Vir Biotechnology which has already been approved for mild to moderate COVID-19 patients in several countries (Australia, Canada, USA), was recently given market authorization by MHRA, UK¹ 감염이 시작된 후 19일 이내에 COVID-5 환자에게 사용하기 위해. 안전하고 효과적인 것으로 밝혀졌으며 입원 위험을 79% 감소시켰습니다. 소트로비맙의 주요 특징은 돌연변이 가능성이 적은 SARS-CoV-2 스파이크 단백질의 고도로 보존된 영역을 표적으로 한다는 점이다. SARS-CoV-2의 이 영역은 SARS-CoV-1(SARS를 유발하는 바이러스)과 공유됩니다.^2, indicating that the region is highly conserved, thereby making it more difficult for resistance to develop. This feature makes sotrovimab to work against all the 변종 of COVID-19 available so far, including 오 미크론. It should also work on any future 변종 as well, as long as the mutations do not occur in the conserved region³ 지금까지 볼 수 없었던 SARS-CoV-2의 스파이크 단백질.

Sotrovimab can thus act as a magic bullet against the all known and future unknown 변종 (that are inevitable as virus accumulates more mutations by higher transmission) of COVID-19. The principle of developing sotrovimab by targeting the conserved region of the spike protein, can be exploited for further development of monoclonal antibodies and vaccines against COVID-19.

***

참조 :